Table 1.
Patient characteristics by different prescribed dose groups.
| Characteristic | 120–140 Gy (n = 21) | 140–160 Gy (n = 41) | Total (n = 62) | P value |
|---|---|---|---|---|
| Sex (n) | 0.469 | |||
| Male | 11 | 25 | 36 | |
| Female | 10 | 16 | 26 | |
| KPS* | 50(40–90) | 50(40–80) | 50 (40–90) | 0.969 |
| Age (years) * | 59(40–74) | 58(36–77) | 58.5 (36–77) | 0.954 |
| Tumor diameter (cm) * | 3.9(1.6–8.5) | 3.3(2.1–7.2) | 3.6(1.6–8.5) | 0.343 |
| Tumor location | 0.965 | |||
| Frontal lobe | 6 | 12 | 18 | |
| Parietal lobe | 7 | 13 | 20 | |
| Occipital lobe | 2 | 6 | 8 | |
| Temporal lobe | 6 | 13 | 19 | |
| Previous treatment | 0.680 | |||
| S+R+T | 18 | 37 | 55 | |
| R+T | 3 | 4 | 7 | |
| MGMT status | 0.678 | |||
| Methylated | 6 | 11 | 17 | |
| Unmethylated | 7 | 17 | 24 | |
| Unknown | 8 | 13 | 21 | |
| IDH1 mutation | 1.000 | |||
| Mutated | 1 | 2 | 3 | |
| Wild type | 11 | 24 | 35 | |
| Unknown | 9 | 15 | 24 |
S, surgery; R, radiotherapy; T, temozolomide. * = median (range).